Key result
Edaravone significantly reduced the proportion of dead rabbit cardiomyocytes following hypoxia and reoxygenation from 51.3% to 39.9% when applied throughout the experiment (P<0.01).
Why the study?
Does edaravone reduce cell death and ROS generation in isolated rabbit cardiomyocytes subjected to hypoxia-reoxygenation injury?
Does edaravone reduce cell death and ROS generation in isolated rabbit cardiomyocytes subjected to hypoxia-reoxygenation injury?
Absolute Event Rate: 39.9% vs 51.3%
p-value: p=<0.01
Edaravone directly protects cardiomyocytes from ischemia/reperfusion injury by attenuating ROS production when applied at or before the time of reoxygenation.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for edaravone in myocardial ischemia-reperfusion; prospective trials needed before clinical consideration.
Yamawaki et al. (2004) studied Hypoxia-reoxygenation injury. Edaravone vs. Control (hypoxia and reoxygenation without edaravone) was evaluated on Proportion of dead cells (p=<0.01). Edaravone significantly reduced the proportion of dead rabbit cardiomyocytes following hypoxia and reoxygenation from 51.3% to 39.9% when applied throughout the experiment (P<0.01).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: